Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 7/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | YES1 | P07947 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | ROS1 | P08922 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665253 | 0.92 | FGFR1 (0.33) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL16659627 | 0.89 | FGFR3 (0.33) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL28767434 | 0.88 | FGFR1 (0.33) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL16654403 | 0.88 | FGFR4 (0.41) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL28767438 | 0.87 | FGFR3 (0.42) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL28768907 | 0.85 | FGFR3 (0.40) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL16655847 | 0.85 | FGFR4 (0.42) | FGFR3FGFR4CYP3A4CYP2C19FGFR1 | |
| SCHEMBL16655438 | 0.82 | FGFR1 (0.44) | FGFR4CYP2C19FGFR1 | |
| SCHEMBL22157649 | 0.82 | FGFR4 (0.32) | FGFR4FGFR1 | |
| SCHEMBL16655790 | 0.82 | FGFR1 (0.44) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498916-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-11-15 | — | — | US | disclosed |
| CN-109422760-B | FGFR4 inhibitor and application thereof | 南京圣和药物研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-107660200-B | Crystalline FGFR4 inhibitor compounds and uses thereof | 卫材R&D管理有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| EP-3283465-B1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MAN CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200317645-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| EP-3057943-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057938-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057938-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498916-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR4 1/4885CYP3A4 691/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR4 1/4885CYP3A4 929/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR4 1/4885CYP3A4 929/4885 |
| US-20200317645-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR4 1/4885CYP3A4 691/4885 |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR4 1/4885CYP3A4 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.